![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
University of Washington National Institutes of Health (NIH) |
---|---|
Information provided by: | University of Washington |
ClinicalTrials.gov Identifier: | NCT00723229 |
We propose to study the episode rate, duration, and quantity of HSV-2 genital shedding in patients taking standard, FDA approved, CDC recommended doses of acyclovir (400 mg PO BID) for HSV-2 suppression compared to taking no medication to better define the effect of acyclovir on short bursts of rapidly cleared HSV-2 shedding. This study will be a randomized, open label, cross-over trial. We hypothesize that short bursts of HSV-2 reactivation will not be suppressed by acyclovir.
Condition | Intervention | Phase |
---|---|---|
Genital Herpes |
Drug: acyclovir |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Crossover Assignment, Efficacy Study |
Official Title: | A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of Acyclovir on Rapidly Cleared Herpes Simplex Virus Type 2 Genital Reactivation Episodes in Herpes Simplex Virus-2 Seropositive Adults |
Estimated Enrollment: | 50 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | September 2011 |
Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: acyclovir
Acyclovir 400 mg PO BID for 28 days
|
2: No Intervention |
We propose to study the episode rate, duration, and quantity of HSV-2 genital shedding in patients taking standard, FDA approved, CDC recommended doses of acyclovir (400 mg PO BID) for HSV-2 suppression compared to taking no medication to better define the effect of acyclovir on short bursts of rapidly cleared HSV-2 shedding. This study will be a randomized, open label, cross-over trial.
We propose to perform this study in two study populations. Cohort 1 will be comprised of 25 HSV-2 seropositive, HIV seronegative adults, and Cohort 2 will be comprised of 25 HSV-2 seropositive, HIV seropositive adults with a CD4 count>250 cells/mm3. As suppression of HSV-2 using acyclovir is currently being studied in large, multi-center, international clinical trials as an HIV prevention strategy, these results will have broad implications for public health around the world.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
COHORT 1: HIV seronegative
COHORT 2: HIV seropositive
Exclusion Criteria:
For both cohorts:
For cohort 2:
Contact: Christine Johnston, MD, MPH | 206-720-4340 | cjohnsto@u.washington.edu |
United States, Washington | |
University of Washington Virology Research Clinic | Recruiting |
Seattle, Washington, United States, 98122 | |
Contact: Christine Johnston, MD, MPH 206-720-4340 cjohnsto@u.washington.edu | |
Principal Investigator: Christine Johnston, MD, MPH |
Principal Investigator: | Christine Johnston, MD, MPH | University of Washington |
Responsible Party: | University of Washington ( Christine Johnston, MD, MPH ) |
Study ID Numbers: | 34187-B |
Study First Received: | July 23, 2008 |
Last Updated: | February 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00723229 History of Changes |
Health Authority: | United States: Institutional Review Board |
Genital Diseases, Female Virus Diseases Herpes Simplex Sexually Transmitted Diseases, Viral Acyclovir Herpes Genitalis |
Sexually Transmitted Diseases DNA Virus Infections Genital Diseases, Male Antiviral Agents Herpesviridae Infections |
Herpes Simplex Anti-Infective Agents Sexually Transmitted Diseases, Viral Herpes Genitalis Genital Diseases, Male Antiviral Agents Pharmacologic Actions |
Herpesviridae Infections Virus Diseases Genital Diseases, Female Acyclovir Therapeutic Uses Sexually Transmitted Diseases DNA Virus Infections |